GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections.
 
Conference details are as follows:
 
Date: Wednesday, April 20, 2016
Time: 9:30 a.m. U.S. Eastern Time
Location: J.W. Marriott Essex House, New York City
 
About Novavax
 
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
 
Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com  
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com 
todd.davenport@russopartnersllc.com
212-845-4271



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#2003007
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Novavax Charts.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Novavax Charts.